Prediction of the drug-drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

• Үндсэн зохиолчид: Loeckie De Zwart (Зохиогч), Jan Snoeys (Зохиогч), Frank Jacobs (Зохиогч), Lilian Y. Li (Зохиогч), Italo Poggesi (Зохиогч), Peter Verboven (Зохиогч), Ivo Goris (Зохиогч), Ellen Scheers (Зохиогч), Inneke Wynant (Зохиогч), Mario Monshouwer (Зохиогч), Rao N. V. S. Mamidi (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Wiley, 2021-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Abstract Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotein (AGP) and is primarily metabolized by cytoch...